Domingo-Domènech Eva, González-Barca Eva, Estany Cristina, Sureda Ana, Besalduch Joan, Fernández de Sevilla Alberto
Haematologica. 2002 Nov;87(11):1229-30.
We studied the safety and efficacy of combined treatment with rituximab plus CHOP in 16 patients with relapsed advanced-stage follicular lymphomas. The intent-to-treat overall response rate (ORR) was 88%, 75% complete remissions (CR) and 13% partial remissions (PR). At a median follow-up of 18 months, 63% of the patients are alive (50% CR). The combination of rituximab and CHOP in relapsed advanced-stage follicular lymphomas achieves high ORRs and CRs, with low toxicity except for in previously autografted patients.
我们研究了利妥昔单抗联合CHOP方案治疗16例复发晚期滤泡性淋巴瘤患者的安全性和疗效。意向性治疗的总缓解率（ORR）为88%，完全缓解（CR）率为75%，部分缓解（PR）率为13%。中位随访18个月时，63%的患者存活（50%为CR）。利妥昔单抗与CHOP联合用于复发晚期滤泡性淋巴瘤可实现高ORR和CR，除既往接受过自体造血干细胞移植的患者外，毒性较低。
Zotero 插件